What are your top takeaways in Medical Oncology from SABCS 2025?

1. lidERA trial. This is the first phase III trial showing an advantage for an oral SERD giredestrant over standard endocrine adjuvant therapy in early breast cancer. Treatment with giredestrant led to a 30% reduction in the risk of invasive disease recurrence over standard endocrine therapy at the fir...

I think that the lidERA study is probably the most exciting advance from the meeting. Having a new antiestrogen medication for early stage HR positive breast cancer, which is more effective than our current standards, will ultimately cure more patients, who make up the majority of early-stage breast...

My top takes are the results of the lidERA and Her2climb-05 trials.

1. Oral SERDs are finally practice-changing in early HR+ disease (lidERA/EMBER-3)

Phase III data from lidERA showed that the oral SERD giredestrant significantly improved invasive DFS compared with standard adjuvant endocrine therapy in ER+/HER2- early breast cancer. Benefit was consistent across key...

1. DESTINY-Breast09: T-DXd + pertuzumab in first-line HER2+ metastatic.

This trial is a rare dataset that rewrites the opening move in HER2+ metastatic disease. The reported PFS separation was large enough that it pushes the field to consider an ADC-forward first-line default, not just “save T-DXd fo...

There were many new findings from clinical trials and other research at the SABCS 2025. I summarize a few highlights.

General Session 1, on Wednesday morning, December 10, 2025, was especially packed with new information:

1. Based on Erica Hamilton’s presentation of the results from HER2CLIMB (GS1-01)...